Production of virus-like particles for vaccines

Ulmer, 2006, Vaccine manufacturing: challenges and solutions, Nat Biotechnol, 24, 1377, 10.1038/nbt1261

Mäkelä, 2000, Vaccines, coming of age after 200 years, FEMS Microbiol Rev, 24, 9, 10.1016/S0168-6445(99)00025-X

Plotkin, 2014, History of vaccination, Proc Natl Acad Sci U S A, 2014, 1

Schiller, 2015, Raising expectations for subunit vaccine, J Infect Dis, 211, 1373, 10.1093/infdis/jiu648

Liu, 2003, REVIEW DNA vaccines: a review, J Intern Med, 253, 402, 10.1046/j.1365-2796.2003.01140.x

Roldao, 2010, Virus-like particles in vaccine development, Expert Rev Vaccines, 9, 1149, 10.1586/erv.10.115

Lua, 2014, Bioengineering virus-like particles as vaccines, Biotechnol Bioeng, 111, 425, 10.1002/bit.25159

Abdoli, 2013, Human papillomavirus type16- L1 VLP production in insect cells, Iran J Basic Med Sci, 16, 891

Cervera, 2013, Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium, J Biotechnol, 166, 152, 10.1016/j.jbiotec.2013.05.001

Liu, 2013, Use of baculovirus expression system for generation of virus-like particles: successes and challenges, Protein Expr Purif, 90, 104, 10.1016/j.pep.2013.05.009

Hu, 2016, Generation and immunogenicity of porcine circovirus type 2 chimeric virus-like particles displaying porcine reproductive and respiratory syndrome virus GP5 epitope B, Vaccine, 34, 1896, 10.1016/j.vaccine.2016.02.047

Yan, 2015, The application of virus-like particles as vaccines and biological vehicles, Appl Microbiol Biotechnol, 99, 10415, 10.1007/s00253-015-7000-8

Aires, 2006, Production of human papillomavirus type 16 L1 virus-Like particles by recombinant lactobacillus casei cells production of human papillomavirus type 16 L1 virus-Like particles by recombinant lactobacillus casei cells, Appl Environ Microbiol, 72, 745, 10.1128/AEM.72.1.745-752.2006

Tan, 2004, E. coli-expressed recombinant norovirus capsid proteins maintain authentic antigenicity and receptor binding capability, J Med Virol, 74, 641, 10.1002/jmv.20228

Saraswat, 2016, Expression and characterization of yeast derived chikungunya virus like particles (CHIK-VLPs) and its evaluation as a potential vaccine candidate, PLoS Negl Trop Dis, 10, 1, 10.1371/journal.pntd.0004782

Luna, 2013, Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women, PLoS One, 8

Felberbaum, 2015, The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors, Biotechnol J, 10, 702, 10.1002/biot.201400438

Metz, 2013, Effective chikungunya virus-like particle vaccine produced in insect cells, PLoS Negl Trop Dis, 7

Buonaguro, 2006, Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses, J Virol, 80, 9134, 10.1128/JVI.00050-06

Maranga, 2003, Virus-like particle production at low multiplicities of infection with the baculovirus insect cell system, Biotechnol Bioeng, 84, 245, 10.1002/bit.10773

Yang, 2012, HIV-1 virus-like particles produced by stably transfected drosophila S2Cells: a desirable vaccine component, J Virol, 86, 7662, 10.1128/JVI.07164-11

Pushko, 2007, Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza, Vaccine, 25, 4283, 10.1016/j.vaccine.2007.02.059

Shen, 2013, Virus-free transient protein production in Sf9 cells, J Biotechnol, 171, 61, 10.1016/j.jbiotec.2013.11.018

Zhu, 2012, Mammalian cell protein expression for biopharmaceutical production, Biotechnol Adv, 30, 1158, 10.1016/j.biotechadv.2011.08.022

Wurm, 2004, Production of recombinant protein therapeutics in cultivated mammalian cells, Nat Biotechnol, 22, 1393, 10.1038/nbt1026

Jayapal, 2007, Recombinant protein therapeutics from CHO cells — 20 years and counting, CEP Mag, 40

Li, 2010, Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice, Vaccine, 28, 4294, 10.1016/j.vaccine.2010.04.025

Fontana, 2015, Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate, Vaccine, 33, 4238, 10.1016/j.vaccine.2015.03.088

Thompson, 2013, Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches, Virol J, 10, 141, 10.1186/1743-422X-10-141

Gutiérrez-Granados, 2016, Optimized production of HIV-1 virus-like particles by transient transfection in CAP-T cells, Appl Microbiol Biotechnol, 100, 3935, 10.1007/s00253-015-7213-x

JK-C, 2003, The production of recombinant pharmaceutical proteins in plants, Nat Rev Genet, 4, 794, 10.1038/nrg1177

Liu, 2005, Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants, Acta Biochim Biophys Sin (Shanghai), 37, 153, 10.1093/abbs/37.3.153

D’Aoust, 2010, The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza, Plant Biotechnol J, 8, 607, 10.1111/j.1467-7652.2009.00496.x

Greco, 2007, Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine, Vaccine, 25, 8228, 10.1016/j.vaccine.2007.09.061

Huang, 2005, Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses, Vaccine, 23, 1851, 10.1016/j.vaccine.2004.11.017

Fruit, 2006, Production of rotavirus-like particles in, Tomato, 19, 42

Schädlich, 2009, Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity, Vaccine, 27, 1511, 10.1016/j.vaccine.2009.01.014

Leavitt, 1985, Polyoma virus major capsid protein, VP1: Purification after high level expression in Escherichia coli, J Biol Chem, 260, 12803, 10.1016/S0021-9258(17)38948-2

Mortola, 2004, Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system, FEBS Lett, 576, 174, 10.1016/j.febslet.2004.09.009

Aucoin, 2007, Virus-like particle and viral vector production using the baculovirus expression vector system/insect cell system: adeno-associated virus-based products, Methods Mol Biol, 388, 281, 10.1007/978-1-59745-457-5_14

Taube, 2005, Generation of recombinant Norovirus-like particles (VLP) in the human endothelial kidney cell line 293T, Arch Virol, 150, 1425, 10.1007/s00705-005-0517-x

Holzer, 2003, Overexpression of hepatitis B virus surface antigens including the preS1 region in a serum-free Chinese hamster ovary cell line, Protein Expr Purif, 29, 58, 10.1016/S1046-5928(03)00011-1

Warzecha, 2003, Oral immunogenicity of human papillomavirus-like particles expressed in potato, J Virol, 77, 8702, 10.1128/JVI.77.16.8702-8711.2003

Huang, 2006, Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice, Vaccine, 24, 2506, 10.1016/j.vaccine.2005.12.024

Ye, 2006, Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies, Virology, 351, 260, 10.1016/j.virol.2006.03.021

Cervera, 2015, Extended gene expression by medium exchange and repeated transient transfection for recombinant protein production enhancement, Biotechnol Bioeng, 112, 934, 10.1002/bit.25503

Eibl, 2010, Disposable bioreactors: the current state-of-the-art and recommended applications in biotechnology, Appl Microbiol Biotechnol, 86, 41, 10.1007/s00253-009-2422-9

Francis, 1995, Hepatitis B virus immunopathogenesis, Annu Revi Immunol, 13, 29, 10.1146/annurev.iy.13.040195.000333

Michel, 2010, Hepatitis B vaccines: protective efficacy and therapeutic potential, Pathol Biol, 58, 288, 10.1016/j.patbio.2010.01.006

Galibert, 1979, Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli, Nature, 281, 646, 10.1038/281646a0

Zhou, 2006, Molecular characterization of recombinant Hepatitis B surface antigen from Chinese hamster ovary and Hansenula polymorpha cells by high-performance size exclusion chromatography and multi-angle laser light scattering, J Chromatogr B, 838, 71, 10.1016/j.jchromb.2006.03.064

Chua, 2012, Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses, PLoS One, 7, 1, 10.1371/journal.pone.0047492

Hawkes, 2015, European Medicines Agency approves first malaria vaccine, BMJ, 351, h4067, 10.1136/bmj.h4067

Morrison, 2015, Landmark green light for Mosquirix malaria vaccine, Nat Biotechnol, 33, 1015, 10.1038/nbt1015-1015

Harper, 2004, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet, 364, 1757, 10.1016/S0140-6736(04)17398-4

Einstein, 2009, Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years, Hum Vaccin, 5, 705, 10.4161/hv.5.10.9518

Schiller, 2006, Chapter 17: Second generation HPV vaccines to prevent cervical cancer, Vaccine, 24, 147, 10.1016/j.vaccine.2006.05.123

Bright, 2007, Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin, Vaccine, 25, 3871, 10.1016/j.vaccine.2007.01.106

Marsian, 2016, Molecular pharming-VLPs made in plants, Curr Opin Biotechnol, 37, 201, 10.1016/j.copbio.2015.12.007

Sundquist, 2015

Doan, 2005, Virus-like particles as HIV-1 vaccines, Rev Med Virol, 15, 75, 10.1002/rmv.449

Weber, 1995, Immunogenicity of the yeast recombinant p17 p24:Ty virus-like particles (p24-VLP) in healthy volunteers, Vaccine, 13, 831, 10.1016/0264-410X(94)00061-Q

Zhang, 2011, Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine, Sci China Life Sci, 54, 1042, 10.1007/s11427-011-4244-0

Tagliamonte, 2011, HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line, Vaccine, 29, 4913, 10.1016/j.vaccine.2011.05.004

Rogo, 2014, Human parvoviru B19: a review, Acta Virol, 60, 49

Herbst-Kralovetz, 2010, Norwalk virus-like particles as vaccines, Expert Rev Vaccines, 9, 299, 10.1586/erv.09.163

Ho, 2004, Assembly of human severe acute respiratory syndrome coronavirus-like particles, Biochem Biophys Res Commun, 318, 833, 10.1016/j.bbrc.2004.04.111